- ATEC Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
10-K/A Filing
Alphatec (ATEC) 10-K/A2008 FY Annual report (amended)
Filed: 7 Jul 09, 12:00am
EXHIBIT 10.22
AMENDMENT TO
EXCLUSIVE LICENSE AGREEMENT
This Amendment to the License and Supply Agreement (this “Amendment”) is made as of January 14, 2008 by and among Alphatec Spine, Inc., a Delaware corporation with a principal place of business at 2051 Palomar Airport Road, Suite 100, Carlsbad, California 92008 (“Licensee”), Progressive Spinal Technologies LLC, a limited liability company organized under the laws of the state of Delaware, with an address at 410 East Walnut Street, Suite #8, Perkasie, Pennsylvania 18944 (“Licensor”) and for purposes of Section 7.2 and Section 11.15 hereof only Alphatec Holdings, Inc., a Delaware corporation with a principal place of business at 2051 Palomar Airport Road, Suite 100, Carlsbad, California 92008 (“Holdings”). Capitalized terms undefined herein shall have the meaning ascribed them in the Agreement.
RECITALS
Reference is made to that certain Exclusive License Agreement dated December 18, 2007, between the parties to this Amendment (the “Agreement”).
The Parties desire to amend the Agreement as set forth herein.
Now, therefore, in consideration of the mutual promises set forth herein and for other good and valuable consideration, the receipt and sufficiency of which is acknowledged by the Parties hereto, the Parties hereto agree as follows:
1. | AMENDMENTS |
1.1Amendment and Restatement of Section 1.10.Section 1.10 of the Agreement is hereby deleted and replaced in its entirety with the following language:
“1.10 “Licensed Field” shall mean[***].
1.2 | Addition of Section 4.4.4.The following language shall be added to the Agreement as Section 4.4.4: |
“4.4.4Limitation on the Number of Shares Issued. Notwithstanding anything to the contrary in this Agreement, in no event shall the aggregate number of Shares issued pursuant to this Agreement be greater than 19.9% of the number of shares of Common Stock outstanding on the Effective Date. In the event that an issuance of Shares pursuant to this Agreement would cause an aggregate issuance of Shares that is more than 19.9% of the number of shares Common Stock outstanding on the Effective Date, the Licensee shall make a cash payment to the Licensor equal to the difference between cash value of the Shares that were scheduled to be issued pursuant to this Agreement, and the value of the Shares that were actually issued after giving effect to the limitation set forth in this Section 4.4.4.”
Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting confidential treatment under
Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
2. | MISCELLANEOUS |
In the event of any conflict between the provisions of this Amendment and the Agreement, the provisions of this Amendment shall prevail. Other than as set forth in this Amendment, the remainder of the Agreement shall remain in full force and effect.
[Signature Page Follows]
2
Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting confidential treatment under
Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
IN WITNESS WHEREOF, the Parties and Holdings have caused this Amendment to be executed by their duly authorized representative.
ALPHATEC SPINE, INC. | PROGRESSIVE SPINAL TECHNOLOGIES LLC: | |||||||
By: | /s/ Dirk Kuyper | By: | /s/ E. Skott Greenhalgh | |||||
Name: Dirk Kuyper | Name: E. Skott Greenhalgh | |||||||
Title: President and CEO | Title: CEO | |||||||
ALPHATEC HOLDINGS, INC. | ||||||||
By: | /s/ Dirk Kuyper | |||||||
Name: Dirk Kuyper | ||||||||
Title: President and CEO |
3
Portions of this Exhibit were omitted, as indicated by [***], and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting confidential treatment under
Rule 24b-2 of the Securities Exchange Act of 1934, as amended.